ClinicalTrials.gg
CompletedNCT00558064Updated Jul 8, 2014Results posted

Filtered Trial for Amlodipine Non-responder

A Phase 3 interventional study of telmisartan+amlodipine and amlodipine in Hypertension, sponsored by Boehringer Ingelheim. Completed at 41 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
531
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
24th of 99
531 · median 184
Started
2007
with 6 others
Phase 3
40 of 99
none open now
Registered
31st of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 24th largest by enrollment, is one of 7 that started in 2007, is one of 40 in phase 3, and was the 31st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

To demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to amlodipine 5 mg alone in patients with essential hypertension and inadequately controlled with amlodipine 5 mg monotherapy.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Essential hypertensive patients satisfying all of the following criteria;
  2. Male or Female
  3. Age > 20 years
  4. Outpatient
  5. Patients who are able to stop current anti-hypertensive therapy at Visit 1 if taking any anti-hypertensive medications
  6. Patients with an ability to provide written in accordance with the related laws and guidelines such as Good Clinical Practice (GCP) and the Pharmaceutical Affairs Law.

Exclusion criteria

Exclusion Criteria:

  1. Taking four or more anti-hypertensive medications
  2. Secondary hypertension
  3. Mean seated diastolic blood pressure (DBP) > 114 mmHg and/or mean seated systolic blood pressure (SBP) > 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP \< 90 mmHg at Visit 3.
  4. Sustained ventricular tachycardia or other cardiac arrhythmias
  5. Congestive heart failure patients with the (NYHA) functional class III-IV
  6. History of myocardial infarction or cardiac surgery within last 6 months
  7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months
  8. History of unstable angina within last 3 months
  9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve
  10. History of stroke or within last 6 months
  11. History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy
  12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors
  13. Known to any component of the drug , or a known hypersensitivity to dihydropyridine -derived drugs
  14. Hepatic and/or renal dysfunction
  15. Diagnosed biliary atresia or cholestasis
  16. Hyperkalemia
  17. Dehydration
  18. Sodium deficiency
  19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs)
  20. Patients who cannot change to the restricted administration and dosage during study period
  21. Pre-menopausal women who meet any one of the following 1 - 3:

    • Pregnant or possibly pregnant (1)
    • Nursing (2)
    • Desire to become pregnant during study period (3)
  22. Drug or alcohol dependency
  23. Complication of malignant tumour or a disease requiring
  24. Compliance of \< 80% or > 120% during the run-in period
  25. Receiving any investigational therapy within 3 months
  26. Judged to be inappropriate by the investigator or the sub-investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
531 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing)

    The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.

    Time frame: Baseline and 8 Weeks

Secondary outcomes

  1. Reduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing)

    The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.

    Time frame: Baseline and 8 Weeks

  2. Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)

    Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake

    Time frame: 8 weeks

  3. Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)

    Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake

    Time frame: 8 weeks

  4. Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)

    Adequate response defined that seated trough diastolic blood pressure was \<90 mmHg or decreased from reference baseline by \>=10 mmHg at 8 weeks

    Time frame: 8 weeks

  5. Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks

    Adequate response defined that seated trough systolic blood pressure was \<140 mmHg or decreased from reference baseline by \>=20 mmHg at 8 weeks (0 percent at baseline)

    Time frame: 8 weeks

  6. Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)

    Optimal, normal, high normal blood pressure were defined as follows: * Optimal: Systolic blood pressure (SBP) \< 120 mmHg and diastolic blood pressure (DBP) \< 80 mmHg * Normal: SBP \>= 120 mmHg or DBP \>= 80 mmHg and SBP \< 130 mmHg and DBP \< 85 mmHg * High normal: SBP \>= 130 mmHg or DBP \>= 85 mmHg and SBP \< 140 mmHg and DBP \< 90 mmHg * No: SBP \>= 140 mmHg and DPB \>= 90 mmHg

    Time frame: 8 weeks

  7. Clinically Relevant Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG

    Clinical relevant abnormalities for blood chemistry, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.

    Time frame: First administration of randomised treatment to 24 hours post last dose of randomised treatment

07

Results

Posted Feb 1, 2010

Participant flow

Participant flow — Overall Study
MilestoneTelmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg Monotherapy
Started269262
Completed264257
Not completed55
Withdrew: Adverse event32
Withdrew: Lack of efficacy01
Withdrew: Protocol violation10
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject01
Withdrew: No visit within allowance period10

Outcome measures

PrimaryReduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing)

The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.

Time frame:
Baseline and 8 Weeks
Reported as:
Mean · mmHg
Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing)
mmHgTelmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg Monotherapy
Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing)9.56 ± 0.614.45 ± 0.61
Statistical analysis
  • Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination vs Amlodipine 5 mg Monotherapy · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 5.11 · 95% CI 3.98 to 6.23Difference calculated as telmisartan 40 mg plus amlodipine 5 mg fixed-dose combination minus amlodipine 5 mg monotherapy
SecondaryReduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing)

The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.

Time frame:
Baseline and 8 Weeks
Reported as:
Mean · mmHg
Reduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing)
mmHgTelmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg Monotherapy
Reduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing)13.04 ± 0.885.77 ± 0.88
SecondaryPercentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)

Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake

Time frame:
8 weeks
Reported as:
Number · percentage of patients
Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)
percentage of patientsTelmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg Monotherapy
Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)68.147.1
SecondaryPercentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)

Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake

Time frame:
8 weeks
Reported as:
Number · percentage of patients
Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)
percentage of patientsTelmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg Monotherapy
Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)67.145.8
SecondaryPercentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)

Adequate response defined that seated trough diastolic blood pressure was \<90 mmHg or decreased from reference baseline by \>=10 mmHg at 8 weeks

Time frame:
8 weeks
Reported as:
Number · percentage of patients
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
percentage of patientsTelmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg Monotherapy
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)74.550.2
SecondaryPercentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks

Adequate response defined that seated trough systolic blood pressure was \<140 mmHg or decreased from reference baseline by \>=20 mmHg at 8 weeks (0 percent at baseline)

Time frame:
8 weeks
Reported as:
Number · percentage of patients
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks
percentage of patientsTelmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg Monotherapy
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks79.558.4
SecondaryPercentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)

Optimal, normal, high normal blood pressure were defined as follows: * Optimal: Systolic blood pressure (SBP) \< 120 mmHg and diastolic blood pressure (DBP) \< 80 mmHg * Normal: SBP \>= 120 mmHg or DBP \>= 80 mmHg and SBP \< 130 mmHg and DBP \< 85 mmHg * High normal: SBP \>= 130 mmHg or DBP \>= 85 mmHg and SBP \< 140 mmHg and DBP \< 90 mmHg * No: SBP \>= 140 mmHg and DPB \>= 90 mmHg

Time frame:
8 weeks
Reported as:
Number · percentage of patients
Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)
percentage of patientsTelmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg Monotherapy
Optimal11.01.6
Normal24.39.7
High Normal26.623.0
SecondaryClinically Relevant Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG

Clinical relevant abnormalities for blood chemistry, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.

Time frame:
First administration of randomised treatment to 24 hours post last dose of randomised treatment
Reported as:
Number · participants
Clinically Relevant Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG
participantsTelmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg Monotherapy
Alanine aminotransferase increased10
Aspartate aminotransferase increased10
Blood creatine phosphokinase increased20
Blood potassium increased01
Blood urine present10
Liver function test abnormal10
Bradycardia10

Adverse events

Collected over First administration of randomised treatment to 24 hours post last dose of randomised treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination—1/269 (0.4%)25/269 (9.3%)
Amlodipine 5 mg Monotherapy—2/262 (0.8%)34/262 (13%)
Most frequent serious events
Most frequent serious events
EventTelmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg Monotherapy
Angina pectorisCardiac disorders0/2691/262
Cerebellar infarctionNervous system disorders0/2691/262
Guillain-Barre syndromeNervous system disorders1/2690/262
Most frequent other events
Most frequent other events
EventTelmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg Monotherapy
NasopharyngitisInfections and infestations25/26934/262

Baseline characteristics

Age, Continuous
Age, Continuous(years)Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg MonotherapyTotal
Mean57 ± 9.656 ± 9.956.5 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose CombinationAmlodipine 5 mg MonotherapyTotal
Female7276148
Male197186383
08

Study locations

41 sites
  • 1235.13.037 Boehringer Ingelheim Investigational Site
    Azumino, Nagano, Japan
  • 1235.13.023 Boehringer Ingelheim Investigational Site
    Higashiosaka, Osaka, Japan
  • 1235.13.021 Boehringer Ingelheim Investigational Site
    Itabashi-ku, Tokyo, Japan
  • 1235.13.014 Boehringer Ingelheim Investigational Site
    Kashihara, Osaka, Japan
  • 1235.13.038 Boehringer Ingelheim Investigational Site
    Kitaazumi-gun, Nagano, Japan
  • 1235.13.009 Boehringer Ingelheim Investigational Site
    Kiyose, Tokyo, Japan
  • 1235.13.041 Boehringer Ingelheim Investigational Site
    Kobe, Hyogo, Japan
  • 1235.13.035 Boehringer Ingelheim Investigational Site
    Komoro, Nagano, Japan
  • 1235.13.003 Boehringer Ingelheim Investigational Site
    Koriyama, Fukushima, Japan
  • 1235.13.004 Boehringer Ingelheim Investigational Site
    Koriyama, Fukushima, Japan
  • 1235.13.027 Boehringer Ingelheim Investigational Site
    Koriyama, Fukushima, Japan
  • 1235.13.007 Boehringer Ingelheim Investigational Site
    Koshigaya, Saitama,, Japan
  • 1235.13.008 Boehringer Ingelheim Investigational Site
    Koto-ku, Tokyo, Japan
  • 1235.13.005 Boehringer Ingelheim Investigational Site
    Matsudo, Chiba, Japan
  • 1235.13.026 Boehringer Ingelheim Investigational Site
    Mito, Ibaraki, Japan
  • 1235.13.013 Boehringer Ingelheim Investigational Site
    Nagoya, Aichi, Japan
  • 1235.13.016 Boehringer Ingelheim Investigational Site
    Okayama, Okayama,, Japan
  • 1235.13.040 Boehringer Ingelheim Investigational Site
    Osaka, Osaka, Japan
  • 1235.13.025 Boehringer Ingelheim Investigational Site
    Saitama, Saitama, Japan
  • 1235.13.001 Boehringer Ingelheim Investigational Site
    Sapporo, Hokkaido, Japan
  • 1235.13.024 Boehringer Ingelheim Investigational Site
    Sapporo, Hokkaido, Japan
  • 1235.13.028 Boehringer Ingelheim Investigational Site
    Sapporo, Hokkaido, Japan
  • 1235.13.030 Boehringer Ingelheim Investigational Site
    Sapporo, Hokkaido, Japan
  • 1235.13.031 Boehringer Ingelheim Investigational Site
    Sapporo, Hokkaido, Japan
  • 1235.13.033 Boehringer Ingelheim Investigational Site
    Sapporo, Hokkaido, Japan
  • 1235.13.034 Boehringer Ingelheim Investigational Site
    Sapporo, Hokkaido, Japan
  • 1235.13.002 Boehringer Ingelheim Investigational Site
    Sendai, Miyagi, Japan
  • 1235.13.018 Boehringer Ingelheim Investigational Site
    Sendai, Miyagi, Japan
  • 1235.13.019 Boehringer Ingelheim Investigational Site
    Sendai, Miyagi, Japan
  • 1235.13.036 Boehringer Ingelheim Investigational Site
    Shimoina-gun, Nagano, Japan
  • 1235.13.042 Boehringer Ingelheim Investigational Site
    Shinjuku-ku, Tokyo, Japan
  • 1235.13.010 Boehringer Ingelheim Investigational Site
    Shinjyuku-ku, Tokyo, Japan
  • 1235.13.011 Boehringer Ingelheim Investigational Site
    Shinjyuku-ku,Tokyo, Japan
  • 1235.13.022 Boehringer Ingelheim Investigational Site
    Shizuoka, Shizuoka, Japan
  • 1235.13.015 Boehringer Ingelheim Investigational Site
    Suita, Osaka,, Japan
  • 1235.13.017 Boehringer Ingelheim Investigational Site
    Takamatsu, Kagawa, Japan
  • 1235.13.029 Boehringer Ingelheim Investigational Site
    Takamatsu, Kagawa, Japan
  • 1235.13.032 Boehringer Ingelheim Investigational Site
    Takamatsu, Kagawa, Japan
  • 1235.13.012 Boehringer Ingelheim Investigational Site
    Takaoka, Toyama, Japan
  • 1235.13.039 Boehringer Ingelheim Investigational Site
    Takaoka,Toyama, Japan
  • 1235.13.020 Boehringer Ingelheim Investigational Site
    Tsuchiura, Ibaraki, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007 and a primary completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2007
First posted
Nov 14, 2007
Start
Oct 2007
Primary completionActual
Sep 2008
Results first posted
Feb 1, 2010
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00558064
First posted
Nov 14, 2007
Start date
Oct 2007
Primary completion
Sep 2008
Results posted
Feb 1, 2010
Last update
Jul 8, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine

Start the discussion